Turn Therapeutics (TTRX) investor relations material

Company background and leadership

• Founded by a former chronic wound patient with extensive commercial medical experience.

• Developed GX-03, initially for personal chronic wound care, now expanded to broader therapeutic uses.

• Holds 17 issued patents across seven families, with robust IP protection through the late 2040s.

• Assembled a board with top industry experts, including former FDA and CDC leaders.

• Operates with a lean structure, burning less than $300,000 per month and maintaining a strong cash runway through Q3 2027.

Product development and clinical progress

• GX-03 has been used by over 200,000 patients with zero reported adverse events.

• Expanded indications include moderate to severe eczema, toenail fungus, and an undisclosed candidate.

• Recent phase II adaptive trial for eczema showed over 50% inhibition of IL-36 and nearly 70% inhibition of IL-31, key cytokines in atopic dermatitis.

• Achieved 92.6% EASI-50 at four weeks and significant EASI-75 and EASI-90 responses, with no adverse events reported.

• Plans to refine inclusion criteria for future trials and target earlier endpoints based on strong early efficacy.

Market positioning and future plans

• GX-03 positioned as a rapid-acting, non-systemic topical for eczema, potentially used alongside biologics or as an alternative for patients avoiding systemic drugs.

• Pediatric market seen as a major opportunity, pending regulatory approval.

• Toenail fungus indication supported by a 100-patient trial showing 70%-85% effectiveness, with unique nail penetration capability.

• Market opportunity extends beyond current treatments, aiming to create new demand among untreated patients.

• Pipeline expansion expected, with IL-36 and IL-31 inhibition opening doors to additional inflammatory and pruritic conditions.